Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Adaptive Biotechnologies: 3Q Earnings Snapshot

11/10/2020 | 04:17pm EST

SEATTLE (AP) _ Adaptive Biotechnologies Corp. (ADPT) on Tuesday reported a loss of $36.7 million in its third quarter.

On a per-share basis, the Seattle-based company said it had a loss of 27 cents.

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 28 cents per share.

The life-sciences research company posted revenue of $26.3 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $23.4 million.

Adaptive Biotechnologies shares have climbed 57% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $47.02, a rise of 66% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ADPT at https://www.zacks.com/ap/ADPT

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
01/11ADAPTIVE BIOTECHNOLOGIES : Partners With AstraZeneca to Use ImmunoSEQ T-MAP in O..
MT
01/11Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immun..
GL
2020Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare..
GL
2020IQVIA-Quest Diagnostics Joint Venture Q2 Form Marketing Partnership With Adap..
MT
2020ADAPTIVE BIOTECHNOLOGIES : Investor Presentation - December 2020
PU
2020Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of ..
GL
2020ADAPTIVE BIOTECHNOLOGIES : and Collaborators to Present Data from More Than 35 A..
AQ
2020ADAPTIVE BIOTECHNOLOGIES : and Collaborators to Present Data from More Than 35 A..
AQ
2020Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 ..
GL
2020ADAPTIVE BIOTECHNOLOGIES : Preliminary Data from Real-World Study Demonstrate T-..
AQ
More news
Financials (USD)
Sales 2020 94,8 M - -
Net income 2020 -142 M - -
Net cash 2020 509 M - -
P/E ratio 2020 -60,3x
Yield 2020 -
Capitalization 8 903 M 8 903 M -
EV / Sales 2020 88,5x
EV / Sales 2021 52,7x
Nbr of Employees 453
Free-Float 94,2%
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 64,67 $
Last Close Price 65,09 $
Spread / Highest target 13,7%
Spread / Average Target -0,65%
Spread / Lowest Target -29,3%
EPS Revisions
Managers and Directors
NameTitle
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Nancy L. Hill Senior Vice President-Operations
Chad M. Cohen CFO, Principal Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION10.08%8 903
EXACT SCIENCES CORPORATION10.17%23 214
GUARDANT HEALTH, INC.23.60%15 925
INVITAE CORPORATION25.78%9 293
BGI GENOMICS CO., LTD.13.25%8 900
IOVANCE BIOTHERAPEUTICS, INC.10.04%7 490